Jonathan Aschoff
Stock Analyst at Roth Capital
(0.49)
# 4,142
Out of 5,182 analysts
39
Total ratings
24.49%
Success rate
-35.09%
Average return
Main Sectors:
Stocks Rated by Jonathan Aschoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTHS Pelthos Therapeutics | Maintains: Buy | $57 → $55 | $22.99 | +139.23% | 2 | Feb 26, 2026 | |
| GTBP GT Biopharma | Initiates: Buy | $11 | $0.38 | +2,797.02% | 1 | Dec 2, 2024 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $19 → $21 | $9.94 | +111.27% | 2 | Sep 24, 2024 | |
| APVO Aptevo Therapeutics | Maintains: Buy | $199,800 → $106,560 | $5.35 | +1,991,675.70% | 3 | Sep 23, 2024 | |
| BRTX BioRestorative Therapies | Maintains: Buy | $15 → $18 | $0.25 | +7,100.00% | 4 | Aug 14, 2024 | |
| NUWE Nuwellis | Reiterates: Buy | $714 | $1.20 | +59,400.00% | 2 | Aug 13, 2024 | |
| GOVX GeoVax Labs | Initiates: Buy | $500 | $1.27 | +39,270.08% | 1 | Jul 16, 2024 | |
| MBRX Moleculin Biotech | Maintains: Buy | $1,000 | $2.42 | +41,222.31% | 2 | Apr 12, 2024 | |
| CLRB Cellectar Biosciences | Maintains: Buy | $600 → $840 | $2.98 | +28,087.92% | 4 | Mar 28, 2024 | |
| HSDT Solana Company | Maintains: Buy | $3,750 → $18,000 | $1.99 | +904,422.61% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $14.09 | +112.92% | 3 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $200 | $6.60 | +2,930.30% | 1 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $9.86 | +41.99% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28,800 → $86,400 | $1.19 | +7,260,404.20% | 2 | Feb 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $8 | $1.82 | +339.56% | 1 | Jun 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $2.32 | +4,210.34% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $1.08 | +36,937.04% | 1 | Nov 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $38 | $7.48 | +408.02% | 1 | Mar 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $96 | $1.13 | +8,395.58% | 3 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $1.27 | +923.62% | 1 | Dec 19, 2019 |
Pelthos Therapeutics
Feb 26, 2026
Maintains: Buy
Price Target: $57 → $55
Current: $22.99
Upside: +139.23%
GT Biopharma
Dec 2, 2024
Initiates: Buy
Price Target: $11
Current: $0.38
Upside: +2,797.02%
Zevra Therapeutics
Sep 24, 2024
Maintains: Buy
Price Target: $19 → $21
Current: $9.94
Upside: +111.27%
Aptevo Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $199,800 → $106,560
Current: $5.35
Upside: +1,991,675.70%
BioRestorative Therapies
Aug 14, 2024
Maintains: Buy
Price Target: $15 → $18
Current: $0.25
Upside: +7,100.00%
Nuwellis
Aug 13, 2024
Reiterates: Buy
Price Target: $714
Current: $1.20
Upside: +59,400.00%
GeoVax Labs
Jul 16, 2024
Initiates: Buy
Price Target: $500
Current: $1.27
Upside: +39,270.08%
Moleculin Biotech
Apr 12, 2024
Maintains: Buy
Price Target: $1,000
Current: $2.42
Upside: +41,222.31%
Cellectar Biosciences
Mar 28, 2024
Maintains: Buy
Price Target: $600 → $840
Current: $2.98
Upside: +28,087.92%
Solana Company
Mar 5, 2024
Maintains: Buy
Price Target: $3,750 → $18,000
Current: $1.99
Upside: +904,422.61%
Feb 20, 2024
Reiterates: Buy
Price Target: $30
Current: $14.09
Upside: +112.92%
Aug 29, 2023
Reiterates: Buy
Price Target: $200
Current: $6.60
Upside: +2,930.30%
Aug 14, 2023
Reiterates: Buy
Price Target: $14
Current: $9.86
Upside: +41.99%
Feb 14, 2023
Maintains: Buy
Price Target: $28,800 → $86,400
Current: $1.19
Upside: +7,260,404.20%
Jun 15, 2022
Reinstates: Buy
Price Target: $8
Current: $1.82
Upside: +339.56%
Feb 25, 2022
Initiates: Buy
Price Target: $100
Current: $2.32
Upside: +4,210.34%
Nov 24, 2021
Initiates: Buy
Price Target: $400
Current: $1.08
Upside: +36,937.04%
Mar 11, 2021
Initiates: Buy
Price Target: $38
Current: $7.48
Upside: +408.02%
Nov 17, 2020
Downgrades: Sell
Price Target: $96
Current: $1.13
Upside: +8,395.58%
Dec 19, 2019
Initiates: Buy
Price Target: $13
Current: $1.27
Upside: +923.62%